[an error occurred while processing this directive]|[an error occurred while processing this directive]
乳腺癌保乳术后同步加量IMRT前瞻性研究
彭冉, 王淑莲, 金晶, 刘跃平, 王维虎, 宋永文, 任骅, 刘新帆, 李晔雄, 余子豪
100021 北京协和医学院 中国医学科学院肿瘤医院放疗科
A prospective study of intensity-modulated radiotherapy with integrated boost after breast conservative surgery in breast cancer patients
Peng Ran, Wang Shulian, Jin Jing,Liu yueping,Wang Weihu,Song Yongwen,Ren Hua,Liu Xinfan,Li yexiong,Yu Zihao
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing 100021, China Corresponding authors:Li Yexiong, Email:yexiong12@163.com;Wang Shulian,Email:wsl20040118@yahoo.com
Abstract：Objective To prospectively evaluate the efficacy and toxicity of intensity modulatedradiotherapy (IMRT) with integrated boost after conservative surgery in breast cancer patients. MethodsFrom January 2006 to June 2010, 128 patients with stages I-III breast cancer treated with breast conservative surgery were recruited. All patients received whole breast IMRT with integrated tumor bed boost. A total dose of 50 Gy in 25 fractions with 2 Gy per fraction was delivered to the whole breast, while 60 Gy with 2.4 Gy per fraction was delivered to the tumor bed concomitantly. Supraclavicular fossa was irradiated to 50 Gy in 9 patients (7.1%) who had more than 3 involved axillary lymph nodes. 104 patients (81.3%) received chemotherapy. 93(94.9%) of the 98 patients who had positive hormone receptor received endocrine therapy. Cosmetic evaluation is based on the Harvard system. Acute and late toxicities were scored according to CTCAE version 3. Survival rates were calculated by Kaplan-Miere method. Results The following-up rate was 100%. The 5-year locoregional recurrence-free survival, disease-free survival and overall survival was 98.4%, 97.7%, and 95.3%, respectively. The acute skin toxicity was grade 1 in 65.6%, grade 2 in 15.6%, and grade 3 in 2.3% of all patients. Grade 2 radiation pneumonitis (RP) developed in 4.7% of this cohort, grade 1 in 22.5%. Grade 1-2 arm edema developed in 28.9%. One patient (0.8%) developed whole breast depigmentation. Four patients (3.1%) developed chromatosis.77.3% of patients had"excellent or good" cosmetic outcome at 5 years, compared to 85.9% of patients before radiotherapy. However, 28 patients (21.9%) had"fair" cosmetic outcome and 1 patient had"poor" appearance at 5 years. Eighteen patients (14.1%) experienced improved cosmetic outcome at 5 years compare to that before radiotherapy while 34 patients (26.6%) had an inferior appearance. Conclusions IMRT with integrated boost after breast-conserving surgery for breast cancer patients is well tolerated, with relatively good cosmetic outcome and moderate toxicity. Meanwhile, 5-year local control and survival are excellent.
Peng Ran,Wang Shulian,Jin Jing et al. A prospective study of intensity-modulated radiotherapy with integrated boost after breast conservative surgery in breast cancer patients[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 251-255.
[1] Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer:results of a randomized clinical trial in Lyon, France[J]. J Clin Oncol,1997,15(3):963-968. [2] Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer:20-year follow-up of a randomised phase 3 trial[J]. Lancet Oncol, 2015,16(1):47-56.DOI:10.1016/S1470-2045(14)71156-8. [3] van der Laan HP, Dolsma WV, Maduro JH, et al. Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy[J]. Int J Radiat Oncol Biol Phys,2007,68(4):1018-1023.DOI:10.1016/j. ijrobp.2007.01.037. [4] van der Laan HP, Dolsma WV, Schilstra C, et al. Limited benefit of inversely optimised intensity modulation in breast conserving radiotherapy with simultaneously integrated boost[J]. Radiother Oncol,2010,94(3):307-312. DOI:10.1016/j.radonc.2010.01.024. [5] Guerrero M, Li XA, Earl MA, et al. Simultaneous integrated boost for breast cancer using IMRT:a radiobiological and treatment planning study[J]. Int J Radiat Oncol Biol Phys, 2004,59(5):1513-1522. [6] Singla R, King S, Albuquerque K,et al. Simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) in the treatment of early-stage left-sided breast carcinoma[J]. Med Dosim,2006,31(3):190-196.DOI:10.1016/j. meddos.2005.11.001. [7] Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer:long-term results of a randomised trial[J]. Radiother Oncol,2005, 75(1):9-17.DOI:10.1016/j.radonc.2005.01.005. [8] Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer:10-year results of the randomized boost versus no boost EORTC 22881-10882 trial[J]. J Clin Oncol,2007,25(22):3259-3265. DOI:10.1200/JCO.2007.11.4991. [9] Yang Z, Chen J, Xie J, et al. Simultaneous integrated boost in breast conserving radiotherapy:is replanning necessary following tumor bed change?[J]. Tech Cancer Res & Treat,2013,12(2):115-122.DOI:10.7785/tcrt.2012.500309. [10] Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J]. JAMA,2011,305(6):569-575.DOI:10.1001/jama.2011.90. [11] Galimberti V, Cole BF, Zurrida S,et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01):a phase 3 randomised controlled trial[J]. Lancet Oncol,2013,14(4):297-305.DOI:10.1016/S1470-2045(13)70035-4. [12] Cante D, Franco P, Sciacero P,et al. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer[J]. Med Oncol,2013,30(2):518-527.DOI:10.1007/s12032-013-0518-7. [13] McDonald MW, Godette KD, Whitaker DJ, et al. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost[J]. Int J Radiat Oncol Biol Phys,2010,77(2):523-530.DOI:10.1016/j.ijrobp.2009.05.042. [14] Morganti AG, Cilla S, Valentini V, et al. Phase Ⅰ-Ⅱ studies on accelerated IMRT in breast carcinoma:technical comparison and acute toxicity in 332 patients[J]. Radiother Oncol,2009,90(1):86-92.DOI:10.1016/j.radonc.2008.10.017. [15] Grtner R, Jensen MB, Nielsen J, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery[J]. JAMA,2009,302(18):1985-1992.DOI:10. 1001/jama.2009.1568. [16] Lundstedt D, Gustafsson M, Steineck G, et al. Risk factors of developing long-lasting breast pain after breast cancer radiotherapy[J]. Int J Radiat Oncol Biol Phys,2012,83(1):71-78.DOI:10.1016/j.ijrobp.2011.05.065. [17] Mak KS, Chen YH, Catalano PJ,et al. Dosimetric inhomogeneity predicts for long-term breast pain after breast-conserving therapy[J/OL]. Int J Radiat Oncol Biol Phys,2014[2015-03-10].http://www.sciencedirect.com/pii/S036030161400321X.DOI:10.1016/j.ijrobp.2014.05.021. [18] Al-Ghazal SK, Fallowfield L, Blamey RW. Patient evaluation of cosmetic outcome after conserving surgery for treatment of primary breast cancer[J] Br Surg Oncol,1999,25(4):344-346. [19] Krishnan L, Stanton AL, Collins CA, et al. Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy[J]. Cancer,2001,91(12):2282-2287. [20] Sacchini V, Luini A, Tana S,et al. Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer[J]. Eur J Cancer,1991,27(11):1395-1400. [21] Heil J, Dahlkamp J, Golatta M,et al. Aesthetics in breast conserving therapy:do objectively measured results match patients′ evaluations?[J]. Anna Surg Oncol,2011,18(1):134-138.DOI:10.1245/s10434-010-1252-4. [22] Bantema-Joppe EJ, Schilstra C, de Bock GH, et al. Simultaneous integrated boost irradiation after breast-conserving surgery:physician-rated toxicity and cosmetic outcome at 30 months′ follow-up[J]. Int J Radiat Oncol Biol Phys,2012,83(4):e471-477.DOI:10.1016/j.ijrobp. 2012.01.050. [23] Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer:interim results at 2 years[J].Int J Radiat Oncol Biol Phys,2012,82(2):715-723.DOI:0.1016/j.ijrobp.2010.10.068.
2015, Vol. 24 
